Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

302.57 +1.78 (+0.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 197,093
Open 305.26
Bid (Size) 120.49 (200)
Ask (Size) 482.99 (200)
Prev. Close 300.79
Today's Range 300.07 - 308.56
52wk Range 131.67 - 326.63
Shares Outstanding 16,676,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
From Ligand Pharmaceuticals
Via GlobeNewswire
News headline image
XOMA Royalty Announces Closing of Its Acquisition by Ligand
From XOMA Royalty Corporation
Via GlobeNewswire

Performance

YTD
+59.2%
+59.2%
1 Month
-5.6%
-5.6%
3 Month
+30.2%
+30.2%
6 Month
+52.2%
+52.2%
1 Year
+123.5%
+123.5%

More News

Read More
News headline image
3 Overlooked Stocks Positioned for the Next Market Rotation ↗
Via MarketBeat
Topics Artificial Intelligence
News headline image
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned? ↗
Via The Motley Fool
Topics Regulatory Compliance
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Fall on Q1 Revenue and EPS Miss ↗
Via Chartmill
Ligand Pharmaceuticals (NASDAQ:LGND) Passes Minervini Trend Template and Growth Screen ↗
Via Chartmill
News headline image
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Wealth Manager Sells $7 Million of Establishment Labs After Massive Gains. Is This Medical Device Stock a Buy? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
OneSpaWorld Posted Record Revenue for Last Quarter. Why Did a Fund Exit a $21.5 Million Stake? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Genpact Stock a Buy After Hedge Fund Rice Hall James Raised Its Stake by $14 Million? ↗
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Is WaterBridge Stock a Buy After Ranger Investment Raised Its Stake by 345,000 Shares? ↗
Via The Motley Fool
Topics Initial Public Offering
News headline image
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
Ligand (LGND) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Ligand Pharmaceuticals Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Villere St Denis Liquidates $18 Million Euronet Worldwide Stake, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Villere St Denis Dumps 134,000 Tidewater (TDW) Shares Worth $9.3 Million ↗
Via The Motley Fool
Topics Energy Regulatory Compliance
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
CLO Sells LGND 5,000 Shares for $1.0 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rice Hall James Buys QuidelOrtho Stock ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rice Hall James Buys Stride Stock ↗
Via The Motley Fool
News headline image
Ligand Pharma (LGND) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Ligand Pharmaceuticals Incorporated - Common Stock publicly traded?
Yes, Ligand Pharmaceuticals Incorporated - Common Stock is publicly traded.
What exchange does Ligand Pharmaceuticals Incorporated - Common Stock trade on?
Ligand Pharmaceuticals Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ligand Pharmaceuticals Incorporated - Common Stock?
The ticker symbol for Ligand Pharmaceuticals Incorporated - Common Stock is LGND on the Nasdaq Stock Market
What is the current price of Ligand Pharmaceuticals Incorporated - Common Stock?
The current price of Ligand Pharmaceuticals Incorporated - Common Stock is 302.57
When was Ligand Pharmaceuticals Incorporated - Common Stock last traded?
The last trade of Ligand Pharmaceuticals Incorporated - Common Stock was at 08/05/26 04:00 PM ET
What is the market capitalization of Ligand Pharmaceuticals Incorporated - Common Stock?
The market capitalization of Ligand Pharmaceuticals Incorporated - Common Stock is 5.05B
How many shares of Ligand Pharmaceuticals Incorporated - Common Stock are outstanding?
Ligand Pharmaceuticals Incorporated - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.